Introduction
While frequently curable when diagnosed early, recurrent or metastatic PCa is controlled with androgen deprivation therapy targeting the androgen receptor (AR) pathway. Indeed, frequent responses of castration-resistant PCa (CRPC) to steroidogenesis inhibitors (abiraterone) and AR antagonists (enzalutamide) have ushered in the era of AR pathway inhibitors (ARPIs) as first-line therapies in CRPC. Although enzalutamide and abiraterone prolong survival of patients with CRPC, resistance invariably emerges [1-3], most often with rising PSA levels indicative of AR-driven activity, or now increasingly as a non-AR-driven phenotype. Reactivation of the AR-driven activities occurs via intratumoural steroidogenesis or AR genomic alterations (including AR overexpression, gene amplification, mutation and splice variants). AR bypass mechanisms include overactivated glucocorticoid receptor [4] , stress signalling [5] [6] [7] and the PI3K/AKT pathway [4, 8, 9] . Finally, a small proportion of CRPC tumours can evade ARPIs by becoming 'indifferent' to AR signalling, as exemplified by neuroendocrine prostate cancer (NEPC) [2] . As one of the most lethal subtypes of CRPC, the median survival time of patients with NEPC is only 7 months as treatment options are limited to platinum-based chemotherapy [3] . While NEPC is rare (<1%) as the primary form of PCa, it is estimated to be present in up to 20% of patients with CRPC after first-and second-line ARPI therapies [10] . The origin of NEPC is not conclusive, but studies have shown that NEPC and CRPC-adenocarcinoma (AdPC) share similar genomics but different transcriptomes [11] , and that AdPC cells were capable of forming NEPC tumours over time [12, 13] , suggesting that selection pressures of ARPIs induce neuroendocrine (NE) trans-differentiation of AdPC. As a result, the prevalence of NEPC is expected to rise with the applications of more potent anti-androgens.
Unfortunately, there are many challenges that hinder improved treatment of NEPC. Early detection of emergent NEPC remains difficult because NEPC is usually first suspected when patients have PCa recurrence or progression in the setting of a low or non-rising PSA level. Because PSA is the main marker that clinicians use to monitor PCa management, findings of NEPC development that often is not accompanied by PSA aberrations may be too late for many patients. In addition, because NEPC is mostly therapy-induced (t-NEPC), it rarely (if at all) shows early divergence before ARPI treatment and the majority of NEPC is difficult to identify before castration resistance development, especially at the time of initial diagnosis. To complicate this issue, the presence of NE markers alone are not sufficient for NEPC diagnosis [14] . Many prostate AdPC tumours have NE-positive cells or NE foci [15] [16] [17] . AdPC cells can gain NE marker expressions by multiple inducers other than ARPI treatment, such as radiation, chemotherapy and hypoxia under hormonally native conditions (discussed in the 'Microenvironment' section below). In fact, the presence of NE marker-positive cells surrounded by AdPC would not change ARPI treatment. It is only through pathological evaluation that an t-NEPC diagnosis and its subtype can be confirmed. Another difficulty involved in diagnosis is (re-)biopsy, which is usually only performed when clinical suspicion for AR-indifferent tumour progression is high. t-NEPC tends to have visceral metastasis, whereas AdPC has the tendency for bone metastasis, often resulting in distinct spreading patterns; however, it is difficult to gauge the risks and benefits of the site and timing of biopsy given the lack of data to date. To achieve more sensitive and earlier detections, research is focusing on liquid biopsies such as serum chromogranin A levels, t-NEPC-specific circulating tumour cells, and circulating tumour DNA [18, 19] .
Tumour heterogeneity and limited therapeutic avenues are also among the difficulties. t-NEPC heterogeneity has only recently begun to be understood because biopsies are not routinely performed for recurrent or metastatic PCa. The most recent updates for classification of NEPC relies on a combination of pathological [17] and clinical features [11] , indicating a spectrum of this disease that may require distinctive diagnostic and management methods. Furthermore, treatment options for t-NEPC are currently restricted to platinum-based chemotherapies in addition to docetaxel or etoposide, with rapid response but limited increase in patient survival [20, 21] . Recent findings suggest platinum-based chemotherapies are particularly effective in small cell prostatic carcinomas (with the majority being t-NEPC) with combined tumour suppressor defects including tumour protein 53 (TP53), retinoblastoma 1 (RB1) and/or PTEN loss, leading to an average of 2.6 months longer progression-free survival [22] . This is possibly attributable to platinum's DNA crosslinking inhibition mechanisms that may aggravate the already unstable DNA in these hyperproliferating cancer cells, particularly in cells with these tumour suppressor deficiencies. Other than platinumbased chemotherapies, targeted therapies have only entered clinical trials recently and their effects remain to be seen (discussed in the 'Potential therapeutic targets' section below). Given these challenges, therefore, there is an unmet need to better define underlying molecular mechanisms of t-NEPC development in order to develop effective biomarkers and therapeutics. Recent progress in understanding the development of t-NEPC at the molecular level is helpful for constructing molecular models for this phenomenon that entails lineage plasticity, differentiation and proliferation.
Lineage Plasticity
Lineage plasticity of PCa describes a state that allows cells to transform from a luminal epithelial phenotype to other phenotypes. Although it is still controversial as to whether PCa stem cells exist, Nouri et al. [23] recently showed that PCa cells are capable of gaining a reprogrammed stem-like phenotype [23] . By treating several PCa cell lines with the N/ NC stem-transition medium, PCa cells were observed to undergo morphological changes within a week that rendered cells to be insensitive to ARPI treatment as well as highly invasive and metastable. More importantly, their findings showed that this phenotypical change is not only reversible, but also can be further induced to neuronal-like, oligodendrocyte-like and osteoblast-like lineages. Although the factors causing these phenotypical changes are not well defined, these findings show that PCa cells possess lineage plasticity and can differentiate into other lineages as a mechanism to resist ARPI treatment.
Androgen Receptor
The androgen-AR axis is arguably the most important pathway in NEPC. De novo NEPC is extremely rare, with a prevalance of <1%, and hormone-na€ ıve PCa without NE phenotypes do not develop NEPC, indicating that an activated androgen-AR axis suppresses AdPCa from becoming NEPC. In fact, lineage tracing shows that NEPC tumours develop from divergent clonal evolution from AdPC as a result of selection pressures of ARPIs [11] . Patient-derived xenograft models also confirmed that ARPIs could induce NEPC development from AdPC [12] ; however, whether the androgen-AR axis acts merely as a selection pressure for NEPC or regulates lineage plasticity of PCa cells remains unknown. Recently, Mu et al. [24] suggested that ARPIs act as a selection pressure that only leads to NEPC in PCa cells with TP53 and RB1 inactivation, which are the key factors controlling PCa lineage plasticity (discussed in the following section). In an editorial in the same issue as that paper, Kelly and Balk [25] postulate that PCa cells with reduced AR may have survival advantages once their growth becomes AR-independent after ARPI treatment. Kregel et al. [26] , however, suggest that ARPI therapy can induce PCa lineage plasticity via reduced ARmediated transcriptional repression of SOX2, an important embryonic stem cell regulator. Ligand-activated AR suppresses SOX2 expression by direct binding to the SOX2 cis-enhancer region. Further studies indicate that ARPI can also induce SOX2 via upregulation of BRN2 [27] . In fact, AR was implicated as a regulator not only for NEPC, but also for other stem-like properties of PCa such as epithelialmesenchymal transition and epithelial-myeloid transition via interplaying with multiple signalling pathways involved in cell lineage modulations (e.g. Wnt, Nanog, and hedgehog) [28] . In addition, AR can cooperate with the enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2) important for epigenetic plasticity regulation in highly metastatic PCa [29] . The AR-EZH2-NMyc interactions were also reported specifically in NEPC models [30] . These studies highlight the many regulatory roles of AR on tumour cell plasticity. In short, ARPI therapy probably functions both as a selection pressure and inducer of PCa lineage plasticity. It is reasonable to speculate that mutations in other lineage regulators, such as TP53 and RB1, may precede ARPIs to confer AdPC lineage plasticity, while ARPI treatment itself can also exert similar effects.
Retinoblastoma 1 and Tumour Protein 53
Loss or inactivation of RB1 and TP53 play important roles in the development of aggressive PCa and metastasis. One of the earliest findings pointing to these two tumour suppressors was the TRAMP mice model. In this model, metastatic PCa, including tumours with NE features, was observed when the transforming region of SV40 large T antigen (SV40 Tag) was expressed in the prostate epithelium to sequester and inactivate RB1 and TP53 [31] . These mice can develop a range of metastatic tumours, some of which had a luminal epithelial phenotype, while others had NE phenotypes as exemplified by synaptophysin (SYP) expression [32] . Clinically, patients with NEPC had significantly more prevalent mutation/deletion of RB1 (70-90% vs 30%) and TP53 (60-70% vs 30-50%) than patients with AdPC [11, [33] [34] [35] , suggesting that loss of these tumour suppressors may predispose to NEPC; however, because of the prominent roles of RB1 and TP53 in regulating cell cycling and survival, respectively, it was not clear whether loss of RB1 and TP53 actually drives AdPC to NEPC or rather facilitates outgrowth of more highly proliferative tumour cells that have already gained an NE phenotype. Recently, Mu et al. [24] answered this question by showing that RB1 and TP53 loss could induce lineage plasticity in the LNCaP-AR cell-line within 48 h. Concurrently, Ku et al. showed that mice with RB1 knockout could develop tumours initiated by PTEN loss that resembled human NEPC, and the addition of TP53 knockout further enhanced NE phenotypes of their tumours. These findings suggest that loss-of-function of RB1 and TP53 not only lead to hyperproliferation of tumour cells, but also permit lineage plasticity of AdPC tumours that may later gain multiple phenotypes, including NEPC, that can evade ARPI therapy; however, it should be noted that RB1 and TP53 loss confer PCa tumours lineage plasticity but do not drive them toward NEPC specifically. This can be exemplified by the diverse phenotypes of neoplasms observed in mice models [32, 36] as well as DU145 cells, a non-NEPC cell-line derived from brain metastasis with null AR, RB1 and TP53.
Mechanistically, PCa cells with RB1 and TP53 inactivation induce SOX2 expression [24] , a transcription factor implicated in lineage plasticity, reprogramming fibroblasts to induced-pluripotent stem cells [37] . Interestingly, in fibroblasts, RB1 was reported to directly suppress SOX2 by recruiting E2Fs to the SOX2 promoter to suppress its expression [38] , while TP53 was reported to indirectly inhibit SOX2 by upregulating microRNAs [39] . Whether similar mechanisms exist in PCa remain to be elucidated. In addition, elevated SOX2 expression is observed in NEPC mice models [36] as well as in patients with NEPC [40] , suggesting a critical role of this transcription factor of driving PCa lineage plasticity that permits further transformations. Another important upregulated protein under RB1 and TP53 inactivation is EZH2 [36] ; EZH2 was also found to be upregulated in NEPC compared with AdPC in patient samples, and EZH2 inhibitors appeared to be able to exert an NEPC-specific effect [11] and restore ARPI sensitivity in NEPC cells in vitro [36] . Notably, SOX2 and EZH2 overexpression were not only observed in RB1 and TP53 inactivation conditions, but also in other NEPCspecific settings, as will be discussed later, indicating that these two proteins are key downstream effectors in ARPI resistance and aggressive CRPC, and this highlights critical roles in lineage plasticity as a mechanism for ARPI resistance.
N-Myc
The Myc family consists of C-Myc, N-Myc and L-Myc, which encode a group of multi-functional transcriptions factors critical in much human cancer initiation and progression. CMyc is the most commonly expressed of the Myc family because it is almost ubiquitously highly expressed in rapidly proliferating cells. On the one hand, overexpression of C-Myc and PTEN loss enabled lethal metastatic PCa development without NE features [41] . On the other hand, N-Myc was not commonly expressed in AdPC (~5%) but highly enriched in NEPC tumours (~40%) [42] . N-Myc is considered to be neuronal-specific and critical for normal brain development [43] . Recently, two independent groups reported that N-Myc overexpression, in combination with AKT upregulation, can 562 © 2018 The Authors BJU International © 2018 BJU International drive NEPC formation in mice models [30, 44] . In particular, the tumours developed by Dardenne et al. [30] showed a variety of morphologies including AdPC and other foci of poorly differentiated carcinoma with diverse phenotypes and AR expression, suggesting that N-Myc amplification can enable lineage plasticity in PCa and drive development of NEPC. It is possible that NEPC foci observed in these mice models is a result of genomic instability created by PTEN loss and N-Myc amplification, resulting in genomic changes favouring NE differentiation. In support of this hypothesis, N-Myc overexpression in human PCa cell lines reduces androgen response and increases sensitivity to EZH2 inhibitors, a trait that may be NEPC-specific [30] . These results suggest that N-Myc overexpression may permit lineage plasticity.
Microenvironment
As described in the introduction above, LNCaP cells treated with stem-transition medium gain a neural/neural-crest phenotype that allow the cells to undergo further differentiation. Interestingly, LNCaP cells have wild-type RB1, TP53 and N-Myc, and are considered as typical AdPC cells. The advent of LNCaP phenotypic plasticity as a result of stem-transition medium suggest that, in addition to genomic alterations, microenvironment can mediate PCa cell plasticity. This hypothesis is supported by many in vitro studies that evaluated agents as drivers of NEPC. For example, one of the first known inducers of NE trans-differentiating is cAMP [45, 46] , which induced cell morphology changes (appearance of neurosecretory cell-like dense-core granules) as well as production and secretion of neuropeptides (NSE, SYP and CHGA) in a reversible fashion in vitro (LNCaP and C4-2). These findings suggest that AdPC cells can change to neuronal-like phenotypes on treatment of cAMP. Further studies also showed that other growth-inhibiting treatments to PCa cells, such as ARPIs [47, 48] , interleukin-6 [49] [50] [51] , melatonin [52, 53] , hypoxia [54, 55] and AKT inhibition [56] , can all induce NE phenotypes in LNCaP cells. These findings indicate that lineage changes, particularly changes to the NE phenotype, is a common process used by PCa cells in response to microenvironment stimuli, particularly adverse stress events.
Neuroendocrine Differentiation
While genomic and environmental factors can affect AdPC lineage plasticity to enable PCa cells to differentiate into other lineages, one important question is why NE differentiation is a common non-AR-driven lineage destination. A possible explanation is that NE properties play an important role in PCa survival and proliferation, secondary to the androgen-AR axis. In mice, autonomic nerve signals infiltrated in the PCa stroma and tumours could promote PCa survival, invasion, migration and distant metastasis [57] . Clinically, patients with PCa and preneoplastic lesions have increased global nerve density in tumour foci compared with benign regions, and axonogenesis in PCa tumours was correlated with ARPI resistance as well as poor outcome [58] . These findings suggest a potentially important role of neuronal signalling for PCa development. NE tumours, on the other hand, not only have neuronal-like morphologies and interact with the autonomic nerve system, but also secrete factors such as bombesin, chromogranin family peptides, thyroidstimulating hormone-like peptides and calcitonin-gene family peptides [59] . Although the functions of these NE peptides remain to be fully elucidated, some factors such as bombesin, neurotensin, serotonin, calcitonin and thyroid-stimulating hormone may have potential mitogenic effects [60] . In addition, the conditional medium of NEPC cells could promote chemoresistance in surrounding AdPC cells by modulating the PTHrP/p38/Hsp27/AR/p21 axis [61] . Concurrently, benign and tumour-associated NE cells were reported to have increased expressions of survival factors including survivin and Bcl-2 [62] [63] [64] . Although functional analyses of these NE peptides warrant further investigation, it is reasonable to hypothesize that, given the advantages discussed above, NE differentiation confer selection advantage to AdPC cells under the increased stress of ARPI therapy.
With the survival advantages of NE differentiation, our current understanding of this process indicates that several key drivers are involved.
SRRM4
The neural-specific SR-related protein of 100 kDa (SRRM4 aka nSR100) is an alternative splicing factor that promotes neural-specific exon inclusions in genes implicated in neuronal cell differentiations [65] . Specifically, Calarco et al. [65] reported that SRRM4 exerts its functions by binding to its target pre-mRNA transcripts. This alternative splicing factor is also critical for neuronal development in zebrafish and for neural stem and progenitor cell formation, proliferation and neurite extension. Clinically, SRRM4 is highly expressed in CHGA + /SYP + NEPC and minimally expressed in AdPC [66] . In fact, transcriptomic profiling suggests that SRRM4 mRNA upregulation was observed in almost all NEPC tumours [11] . Studies using PDX models suggest that SRRM4 is upregulated in AdPC tumours under prolonged ARPI treatment [67] . The upregulation of many SRRM4-targeted splice variants (e.g. REST4 and PHF21A-2) in NEPC suggests that SRRM4 is functionally active [12, 68] . In fact, the splicing of REST into its inactive form, REST4, by SRRM4 is one mechanism by which SRRM4 drives NE differentiation [69] . In addition to differentiation factors, other SRRM4 target genes include epigenetic histone modifiers, transcription factors and RNA splicing factors [65] ; some of these downstream effectors were shown to induce NE cell proliferation, as discussed in the 'MYST/Esa1-associated factor 6' section below. Together, these findings indicate that SRRM4 is a neuronal-specific alternative splicing factor that drives NE differentiation and NEPC. Given the multifaceted functions of this neuro-specific splicing factor, it probably plays more roles than promoting the differentiation process; whether SRRM4 alone can induce NEPC tumour development and progression from AdPC warrants further investigation.
REST
The repressor element 1 (RE-1) silencing transcription factor (REST) is a master negative regulator of neuronal differentiation [70] . It is a 1097-amino acid protein that binds to the 21-bp RE-1 normally located within the regulatory region of target genes that are often important for a neuronal phenotype [71] . REST is minimally expressed in neuronal and stem cells, but is almost ubiquitously expressed in other adult tissues, suggesting a critical role in controlling cell differentiation fate. Although REST was found to be highly expressed in the prostate and in AdPC cells, it was reported to be significantly downregulated in NEPC patient samples [66, 68] . Downregulation of REST allows the derepression of neuronal-differentiation-related genes, thus leading to NEPC development. Mechanistically, REST may be regulated by ARPIs at both the mRNA and protein levels. At the mRNA level, REST is alternatively spliced by SRRM4, as discussed above [69] , to form an inactive form of REST4 [72] . At the protein level, REST is tightly regulated by a pair of ubiquitinases and deubiquitinases called b-TRCP and HAUSP, respectively [73] [74] [75] ; therefore, ARPI therapy can downregulate REST via upregulation of both SRRM4 and b-TRCP to confer NE-specific differentiation among AdPC cells. Interestingly, REST was also reported to be downregulated in other stress conditions including AKT inhibition [56] , hypoxia [55] and interleukin-6 [49] treatment. These observations not only highlight the important role of REST in regulating PCa lineage differentiation, but also support potential selection advantages of NE differentiation as a major survival mechanism in PCa cells.
BRN2
Another important factor that facilitates NE-specific lineage differentiation in PCa is the POU-domain transcription factor BRN2 [27] . BRN2 is known to promote neuronal differentiation and enhance the expression of corticotropinreleasing hormone regulated genes [76] . Similarly to the neuronal-specific differentiation factors discussed above, BRN2 expression was highly correlated with tumours of NE phenotypes and low PSA expressions in patient cohorts [27] .
Moreover, AR inhibition can directly upregulate BRN2 expression and activity, which in turn activates SOX2 expression to promote therapy resistance and lineage plasticity [27] . Importantly, despite the implications of BRN2 in lineage plasticity and cell growth, the ability of BRN2, but not SOX2, to induce NE marker expressions both in vitro and in vivo [24] indicates that BRN2 can promote NEspecific differentiation, possibly independently of SOX2. These findings together help categorize BRN2 as a neurospecific differentiation factor.
FOXA Family
The FOXA family proteins, in particular FOXA1 and FOXA2, are also implicated in t-NEPC. Although as transcription factors, FOXA1 and FOXA2 share almost identical DNA binding domains, they have differential functions via slight differences in DNA binding affinity, tissue distribution, and co-regulators as reviewed elsewhere [77] . For example, FOXA1 is expressed throughout prostate organogenesis and adult tissues whereas FOXA2 is only expressed during the initial budding stage of the prostate at E18 through day 1 in murine models [78] , suggesting the importance of proper temporal and regional expressions of FOXA1 and FOXA2 in prostate development. In addition, both FOXA1 and FOXA2 were reported to interact with and modulate AR signalling and PCa progression [77] . On the one hand, FOXA1 deletion was observed to cause prostatic hyperplasia and abnormal expression of seminal vesicle associated genes in GEM models [79] . Reduced FOXA1 expression could activate the IL-8-MAPK/ERK pathway in leading to NE differentiation in PCa cell and animal models [80] , suggesting a potentially important role of FOXA1 in prostatic epithelial cellular differentiation maintenance and NE-differentiation suppression. On the other hand, FOXA2 knockout is lethal to mice as it led to failure in organ differentiations during embryonic development [81] . Importantly, increased FOXA2 expressions are reported in NE-like tumours in the TRAMP mouse model [82] and NEPC GEM tumour cells driven by N-Myc and AKT1 overexpression [83] . Clinical findings also support the NEPCspecific expressions of FOXA2 as it was re-expressed in all (100%) tumours in patients with t-NEPC but only in 20% of tumours in patients with AdPC [84] . Interestingly, FOXA2 cooperates with the ubiquitin ligase Siah2 to modulate HIF1a-regulated genes in TRAMP mouse with the NE phenotype [85] . Since HIF-1a is a hypoxia-induced gene and downregulates REST functions, whether FOXA2 could induce NEPC phenotype in PCa cells via the HIF-1a-REST axis warrants further investigation. Nevertheless, given the important regulatory roles of FOXA1/FOXA2 in prostate development and NEPC progression, these FOXA family proteins may represent novel NE-specific differentiation factors that drive AdPC into NEPC. 
Proliferation
Benign NE cells are mostly post-mitotic and have minimal proliferative abilities, similar to those of most neuronal cells [59] . In PCa, cells with NE marker expressions were observed in 30-100% of the PCa population [16, 60] , yet only roughly 25% could be transformed into NEPC under the selection of ARPI therapy [10] . In fact, gains of NE phenotypes often occur during stress periods as an adaptive survival mechanism. In vitro studies found that acquisition of the NE phenotype in PCa cells is often accompanied by reduced proliferation rates with various treatments (ARPIs, AKT, interleukin-6, cAMP, hypoxia); therefore, these observations suggest that NEPC cells may have to gain additional clonal expansion abilities in order to repopulate the tumour. In fact, findings to date indicate that there are several genes that are specific to NEPC because they are upregulated only in NEPC tumour cells but not in AdPC cells, yet they only facilitate cell proliferation and invasion but not NE differentiation when investigated in cell and animal models.
Aurora Kinase A
Aurora kinase A (AURKA) is a mitotic kinase that plays important roles in early mitosis by regulating centrosome function and spindle assembly, thereby promoting cell cycle and proliferation [86] . Upregulation of this oncogene was found in almost all patients with NEPC by mRNA analysis significantly overexpressed in NEPC [42] . Notably, AURKA also plays an important role in stabilizing N-Myc by forming a complex with this putative NEPC driver [30] . Mechanistically, AURKA overexpression in NEPC may be attributable to selection pressure of cells with AURKA amplifications (four out of seven patients with NEPC) [42] as well as increased protein stability via the TP53 mutation and miR25 axis [87] . Interestingly, AURKA overexpression was not reported to be a potent inducer of NE markers, nor did it have significant epigenetic impact to confer AdPC the NE phenotype at the transcriptomic level [42] . These observations suggest that AURKA primarily plays a facilitator role to promote tumour cell proliferation in an NEPC-specific fashion. The AURKA inhibitor MLN8237 is the first NEPCspecific small molecule drug being investigated in a clinical trial and not yet published.
PEG10
The placental gene PEG10 is de-repressed as an adaptive response to ARPI therapy and highly upregulated in NEPC patient samples and xenografts [67] . Akamatsu et al. [67] further demonstrated that PEG10 functionally drives the G0/ G1 cell cycle progression in PCa cells in a TP53-dependent fashion while also promoting cell invasions through the upregulation of Snail expression via the TGF-b signalling; however, PEG10 was not observed to exert an inductive effect on NE differentiation in AdPC cells, therefore, as a potent growth promoter regulated by TP53/RB1 as well as ARPI, PEG10 represents an NEPC-specific facilitator for NE cell clonal expansion and aggressive behaviour, promoting both cell proliferation and invasion.
MYST/Esa1-associated factor 6
An NEPC-specific facilitator for tumour cell proliferation and invasion is MYST/Esa1-associated factor 6 (MEAF6) [88] . MEAF6 is a protein component of the histone acetyltransferase complex and tightly regulated by the NEPC-specific alternative splicing factor SRRM4, which increases levels of the neuralspecific variant MEAF6-1 while reducing MEAF6-2 [88] . The MEAF6-1 isoform is highly expressed in NEPC tumour biopsies and cell models, functioning to promote PCa cell growth and invasion, putatively via the upregulation of ID1 and ID3 genes. Consistent with other proliferation genes, neither MEAF6-1 nor MEAF6-2 induced NE differentiation in AdPC cells. Consequently, MEAF6-1 can be considered as another NEPC-specific proliferation facilitator.
Cyclin D1
Because of the important roles of RB1 in NEPC as discussed in the 'RE-1 silencing transcription factor' section above, it is important to clinically characterize RB1 loss in NEPC tumours. Cyclin D1 is a downstream effector of RB1 (aka CCND1 [89] ) and is highly upregulated in NEPC tumours compared with primary PCa and metastatic AdPC [90] . In addition, Tsai et al. [90] found a strong correlation between RB1 loss and cyclin D1 abundance via the CDKN2A/CCND1 ratio, supporting cyclin D1 as RB1 regulated in PCa. As a regulator of CDK kinases 4/6 activities and a promoter of cell cycle G1/S transition, cyclin D1 may be another important facilitator for NEPC proliferation and tumour establishment; however, functional studies of cyclin D1 in PCa have not yet been defined and need further investigations, especially regarding any potential non-canonical functions of cyclin D1 pertaining to NE differentiation.
Discussion

Complexity within the Model
In the present review, we have proposed a model whereby putative molecular drivers and facilitators of NEPC cooperate in the process of NEPC differentiation and tumour repopulation (Fig. 1) . Genes involved in lineage plasticity (e.g. N-Myc, RB1, and TP53) permit AdPC to evade ARPI in an AR-independent fashion. These genes tend to give rise to various AR-independent phenotypes in PCa. In addition to lineage plasticity, AdPC may require the input of NE-specific differentiation genes to eventually transform into NEPC. SRRM4, REST, BRN2 and FOXA1/2 all play critical roles in determining final lineage of NEPC that have selective advantages among other AR-independent tumours during ARPI treatment. Furthermore, NEPC cells require the ability to outgrow other PCa cells for clonal expansion, tumour repopulation, and treatment resistance. This process may be aided by the expression of NEPC-specific proliferation facilitators such as AURKA, PEG10, MEAF6 and cyclin D1.
Nevertheless, temporal and spatial alterations of these enablers of lineage plasticity, NE differentiation and proliferation in the development of a particular t-NEPC tumour require further investigation. It is possible that only a subset of these genes is sufficient in driving t-NEPC development. Moreover, the three processes proposed in this model are non-linear. For example, fast-growing aggressive RB1/TP53 null tumours have already acquired phenotypic plasticity and may differentiate into NEPC en masse on ARPI treatment. In addition, the functions of these genes discussed in this manuscript are often intertwined. For instance, since the canonical functions of TP53 and RB1 are therapy resistance and cell proliferation, loss of these genes in NEPC do play important roles in NEPC clonal expansion and tumour establishment as well. Another example is the master alternative splicing factor SRRM4, which plays dual critical roles in NE differentiation and proliferation by acting on the REST and MEAF6 gene, respectively. Similarly, AURKA is not directly involved in NE differentiation, but this kinase can stabilize N-Myc, which in turn downregulates the AR signalling pathway to possibly enhance NEPC transformation. Many genes discussed in the present review, therefore, have N E -t r a n s d iff e r e n t ia t io n Fig. 1 Schematic summary of the molecular model for neuroendocrine prostate cancer progression. NEPC, neuroendocrine prostate cancer; AdPC, adenocarcinoma; ARPI, AR pathway inhibitor; t-NEPC, therapy-induced neuroendocrine prostate cancer; NE, neuroendocrine; EZH2, enhancer of zeste homolog 2; Rb, retinoblastoma 1; TP53, tumour protein 53; REST, repressor element 1 silencing transcription factor; AURKA, aurora kinase A; MEAF6, MYST/Esa1-associated factor 6. Nonetheless, the emerging evidence argues for the coordinated lineage plasticity-NE differentiation-proliferation model as the main process of NEPC progression.
Potential Therapeutic Targets
As discussed above, there has not been much success besides platinum-based chemotherapy for t-NEPC. In fact, there are only a handful of targeted therapies for t-NEPC that are currently undergoing clinical trials (Table 1) . While some trials target t-NEPC-specific molecular events, such as AURKA, others, such as rovalpituzumab (DLL3) and avelumab (PD-L1), involve targets previously observed to be effective in small cell lung cancer (SCLC) because of the resemblances between SCLC and t-NEPC to a certain extent [91] . As reviewed by Rickman et al. [91] , both SCLC and NEPC are endodermal in origin [92] , can be therapy-induced via clonal evolutions (NEPC from ARPI [11] and SCLC from EGFR inhibition [93] ), and harbour extensive molecular alterations such as TP53 and RB1 loss, Myc overactivation and EZH2 overexpression. In addition to the ongoing clinical trials, bromodomain and extra-terminal (BET) protein inhibitors such as JQ1 have been studied in both SCLC and NEPC to target Myc activities and tumour growth inhibition [94, 95] . Similarly, epigenetic regulators such as EZH2 and HDAC are also potential common therapeutic targets because both SCLC and NEPC have been shown to have prominent epigenetic reprogramming as a result of lineage plasticity [11, 96] . In fact, EZH2 inhibition in preclinical NEPC models showed marked growth inhibition results [30] .
Beyond the existing studies, characterizing the functional significance(s) of the known genetic and epigenetic drivers of NEPC through our model may provide a way of discovering novel rationales in specifically targeting NEPC development or progression. For example, monotherapies targeting SOX family proteins, such as SOX2, may reduce lineage plasticity in AdPC cells as a consequence of RB1/TP53 loss or BRN2 overexpression in the setting of ARPI. Inhibiting the master NE-specific alternative splicing factor SRRM4 has the potential to inhibit both NE-specific differentiation and proliferation through reduced REST and MEAF6 alternative splicing, respectively. However, targeting only one of the proliferative factors, such as MEAF6-1, may not be ideal because other pro-proliferation drivers can compensate for tumour establishment. A combination therapy, therefore, that targets multiple proliferation factors may be able to stop NEPC tumour establishment by significantly turning off the 'proliferation switch'. Nevertheless, efforts to target these molecular factors may be deterred for biological and technical reasons. Direct Myc inhibitors are difficult to develop because of the expression of Myc family proteins in normal cells [97] . SRRM4-specific inhibitors are currently not feasible because of the lack of crystal structure of SRRM4. In addition, based on the various subtypes of t-NEPC as well as differential temporal and spatial alterations of the key t-NEPC contributing factors, further investigations will be required to find the most appropriate choice and sequence of treatment regimen in patients with t-NEPC.
Conclusion
Studies, primarily over the past decade, have identified multiple molecular alterations that are key to the development and progression to t-NEPC. These molecular alterations can be categorized into a holistic model that includes three coordinated processes: lineage plasticity; NE differentiation; and proliferation. This model may provide new insights into how t-NEPC drivers and facilitators relate to each other and contribute to the emergence to t-NEPC tumours. It also offers a reference for rationales of designing new therapeutic targets of this disease.
